Patents Examined by Venkataraman Balasubramanian
  • Patent number: 10633368
    Abstract: Provided is a synthesis method for a voriconazole intermediate condensate as shown in formula II or an acid addition salt thereof. As shown in reaction formula 1, the product is prepared via compounds III and IV. The synthesis method adjusts the feeding means, and the reaction conditions are mild and controllable, thereby reducing the production of impurity A, avoiding the use of highly toxic metal lead, and eliminating the risk of highly toxic metal remaining in a drug. The product has a higher purity and significant industrial application value.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: April 28, 2020
    Assignee: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
    Inventors: Hu Huang, Wenfeng Huang, Guoliang Tu, Jiegen Liu, Zhongming Xu, Qianghui Wu, Zhaoyang Meng, Yuling Fang
  • Patent number: 10626097
    Abstract: The present invention relates to an improved process for making hydroxyethyl piperazine compounds especially mono-hydroxyethyl piperazine. The improvement comprises reacting piperazine and an alkylene oxide, preferably ethylene oxide in a reactive distillation column.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: April 21, 2020
    Assignee: Dow Global Technologies LLC
    Inventors: John G. Pendergast, Jr., Ravindra S. Dixit, Stephen W. King, Christophe R. Laroche
  • Patent number: 10626110
    Abstract: The present disclosure provides a crystalline form F of Pazopanib HCl, which is characterized by an X-ray diffraction (XRD) pattern having peaks at about 11.3, 14.6, 16.9, 19.5, 19.7, 23.5 and 25.9°±0.2° 2?. The present disclosure also provides a preparation process of a crystalline form F of Pazopanib HCl.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: April 21, 2020
    Assignee: FORMOSA LABORATORIES, INC.
    Inventor: Sheng-Kai Ko
  • Patent number: 10618904
    Abstract: The present invention provides a hydrobromide of methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazol[1,2-a][1,4]benzodiazepine-4-yl] propionate and its related crystal forms, preparation method and use thereof. The hydrobromide has excellent solubility (>100 mg/ml), which is significantly superior to other currently commercially available or developed salt products, and is especially suitable for the preparation of injections, has relatively good stability in various crystal forms, and has good practical value and market prospects.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 14, 2020
    Assignee: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD.
    Inventors: Haoxi Huang, Guoqing Zhuo, Guoning Shang, Zhen Liang, Ting Chu, Cuicui Chen, Ming Luo, Yingfu Li, Zhonghai Su
  • Patent number: 10617690
    Abstract: The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: April 14, 2020
    Assignee: WUXI FORTUNE PHARMACEUTICAL CO., LTD
    Inventors: Hao Wu, Weiwei Mao, Lili Fan, Charles Z. Ding, Shuhui Chen, Fei Wang, Guoping Hu, Jian Li
  • Patent number: 10611769
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: April 7, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • Patent number: 10611738
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 7, 2020
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Patent number: 10604539
    Abstract: Materials which react with (“scavenge”) sulfur compounds, such as hydrogen sulfide and mercaptans, are useful for limiting sulfur-induced corrosion. Surface-modified particles incorporating a hexahydrotriazine moiety are disclosed and used as sulfur scavengers. These surface-modified particles are used a filter media in fixed filter systems and as additives to fluids including sulfur compounds. The hexahydrotriazine moiety can react with sulfur compounds in such a manner as to bind sulfur atoms to the surface-modified particles, thus allowing removal of the sulfur atoms from fluids such as crude oil, natural gas, hydrocarbon combustion exhaust gases, sulfur polluted air and water. The surface-modified particles may, in general, be sized to allow separation of the particles from the process fluid by sedimentation, size-exclusion filtration or the like.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 31, 2020
    Assignee: International Business Machines Corporation
    Inventors: Dylan J. Boday, Jeannette M. Garcia, James L. Hedrick, Rudy J. Wojtecki
  • Patent number: 10604541
    Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 31, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Wei Meng, Mark Liu, Bei Wang, Rulin Zhao
  • Patent number: 10597394
    Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: March 24, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Peng Li, Lawrence P. Wennogle, Robert Davis
  • Patent number: 10597397
    Abstract: The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L1, L2, X1, R1, R2, R3, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in therapy, for example as vaccine adjuvants. The present specification also relates to a process for preparing adenine conjugate compounds and pharmaceutically acceptable salts thereof, and to pharmaceutical compositions comprising adenine conjugate compounds and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 24, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Yukihiro Nishio, Padma Malyala, Bilikallahalli K. Muralidhara, Marcus Wong
  • Patent number: 10577367
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: March 3, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffery Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield
  • Patent number: 10570149
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of ATR, and can be employed for the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 25, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Lars Burgdorf, Dieter Dorsch, Christos Tsaklakidis
  • Patent number: 10570130
    Abstract: The present invention relates to a process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate of the formula (I) and to a process for purifying the crude product of the compound of the formula (I) for use as pharmaceutically active compound, where, for purification, methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate sulphinyldimethane (1:1), i.e. a compound of the formula (II), is isolated as intermediate or is generated as intermediate in this purification process, if appropriate present in a mixture.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: February 25, 2020
    Assignee: Adverio Pharma GmbH
    Inventors: Franz-Josef Mais, Joachim Rehse, Winfried Joentgen, Konrad Siegel
  • Patent number: 10570159
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs).
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: February 25, 2020
    Assignee: Qpex Biopharma, Inc.
    Inventors: Scott J. Hecker, Raja K. Reddy, Tomasz Glinka, Olga Rodny
  • Patent number: 10570142
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: February 25, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Patent number: 10570141
    Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: February 25, 2020
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Shulong Wang, Kuncheng Chen, Xijie Liu, Yuandong Hu, Bo Liu, Yong Peng, Hong Luo, Yongxin Han, Shanchun Wang, Mei Liu, Hongjiang Xu
  • Patent number: 10561662
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 18, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • Patent number: 10566544
    Abstract: Example embodiments provide a compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 18, 2020
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Hiromasa Shibuya, Tatsuya Imase, Rie Sakurai, Xavier Bulliard, Hyesung Choi, Tadao Yagi, Sung Young Yun, Gae Hwang Lee, Kwang Hee Lee, Dong-Seok Leem, Yeong Suk Choi
  • Patent number: 10544186
    Abstract: The invention relates to a process for the production of amide bonds, in particular peptide bonds, with the aid of novel amide linking reagents containing an anion of the formula (I), to the novel reagents, and to the preparation thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: January 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Nikolai Mykola Ignatyev, Walter Frank, Peter Barthen, Myroslav Vysotsky